UroGen Pharma Ltd. (URGN)
NASDAQ: URGNHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 40.80 +0.25%
URGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.99B
- Forward P/E
- 14.57
- EPS (TTM)
- -$1.97
- Dividend yield
- None
- 52-week range
- 15.86 – 50.81
- Day range
- 40.64 – 41.93
- Volume / Avg
- 477.08K / 832.57K
- Beta
- —
- Shares outstanding
- 48.88M
- Next earnings
- Nov 5, 2026
52-week range
URGN stock today
Shares of UroGen Pharma (URGN) finished lower on Oct 7 at $40.70, a drop of 1.76% or $0.73 per share, versus the S&P 500's 0.22% decline. At this level, URGN sits in the middle of its 52-week range of $15.86 to $50.81: 19.9% below the high, set on Aug 19, 2026 and 156.6% above the low. URGN is up 73.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 141.7%.
UroGen Pharma has posted a net loss over the last twelve months (EPS of -$1.97), so its P/E ratio is not meaningful. UroGen Pharma's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About UroGen Pharma
Company profileUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Elizabeth A. Barrett
- Headquarters
- Princeton, NJ
- Employees
- 300
- IPO year
- 2017
- Website
- urogen.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$60.00+47.42%
- Strong buy 1
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $0.38
URGN news
All URGN newsUroGen Pharma peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs URGN |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs URGN |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs URGN |
| NVAXNovavax Inc. | 11.22 | -0.88% | $1.85B | vs URGN |
| STOKStoke Therapeutics Inc. | 24.29 | -0.33% | $1.57B | vs URGN |
| INVAInnoviva Inc. | 21.06 | +1.10% | $1.52B | vs URGN |
| SNDXSyndax Pharmaceuticals Inc. | 17.03 | -1.96% | $1.52B | vs URGN |
| IMCRImmunocore Holdings plc ADR | 29.41 | -0.47% | $1.51B | vs URGN |
Indexes, lists and sector
Appears in lists
UroGen Pharma stock FAQ
What is UroGen Pharma's stock price today?
URGN last traded at $40.70 as of Oct 7, 4:00 PM EDT, down 1.76% on the day. Prices are delayed at least 15 minutes.
When is UroGen Pharma's next earnings date?
UroGen Pharma is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $0.38.
Who is UroGen Pharma's CEO?
Ms. Elizabeth A. Barrett is the chief executive officer of UroGen Pharma Ltd., which has about 300 employees.
What is the URGN 52-week high?
The 52-week high for URGN is $50.81 and the 52-week low is $15.86. The stock is currently 19.9% below its high.